Core Viewpoint - Investing is viewed as a learning process where failures serve as tuition and successes contribute to lessons learned [1] Group 1 - The author has approximately 5 years of focused research on various stocks, with a primary emphasis on healthcare stocks [1] - The author appreciates feedback from readers, especially those sharing relevant anecdotes and experiences [1] Group 2 - The author has a beneficial long position in URGN shares, indicating a personal investment interest [2] - The article expresses the author's own opinions and is not influenced by compensation from any company mentioned [2]

UroGen Pharma FY Conference Summary Company Overview - **Company**: UroGen Pharma (NasdaqGM:URGN) - **Industry**: Biotechnology, specifically focused on bladder cancer treatments Key Highlights - **Transformational Year**: UroGen is experiencing a pivotal year with the approval of JELMYTO for bladder cancer, marking a significant milestone since the company's inception [10][11] - **Financial Position**: The company has successfully completed debt refinancing, enhancing its financial stability and flexibility for future growth [60][61] - **Product Launch**: JELMYTO's launch is unique as it involves a procedure rather than a traditional pill or infusion, impacting the treatment timeline for patients [16][17] Financial Performance - **Q4 Results**: UroGen reported Q4 revenues of approximately $14 million, with $4.5 million generated in October alone, indicating strong initial uptake [19] - **Growth Expectations**: The company anticipates accelerated growth following the introduction of a permanent J-code, which is crucial for reimbursement confidence among physicians [17][20] Market Dynamics - **Patient Enrollment**: About 80% to 90% of patients are processed through a hub that manages patient enrollment forms, which are critical for tracking demand [23][25] - **Conversion Rates**: The conversion rate from patient enrollment forms to actual treatments is currently around 70%-80%, with efforts to reduce the time from enrollment to treatment [31][25] Competitive Landscape - **Unique Positioning**: UroGen is the only company offering a treatment for low-grade non-muscle invasive bladder cancer, differentiating itself from competitors [18] - **Market Potential**: The bladder cancer market is estimated to be a $5 billion opportunity, with UroGen aiming to capture a significant share through its innovative treatments [35][36] Pipeline Developments - **UGN-103**: This next-generation formulation is expected to have patent protection until 2042, with clinical data anticipated mid-year [66] - **UGN-501**: An oncolytic virus with potential applications beyond bladder cancer, currently in early development stages [70][71] Strategic Vision - **Long-term Growth**: UroGen aims to build a sustainable growth company by leveraging its unique product offerings and expanding its market presence [10][12] - **Focus on Education**: The company is committed to educating physicians on the benefits of its treatments to drive adoption and increase patient access [35][46] Undervalued Aspects - **Market Valuation**: The CEO highlighted that the market valuation does not fully reflect the potential of ZUSDURI, which could represent a $1.2 billion opportunity if the company captures 20% of the patient population [76] Conclusion - UroGen Pharma is positioned for significant growth in the bladder cancer treatment market, with a strong financial foundation, innovative products, and a strategic focus on education and market penetration. The upcoming quarters will be critical in determining the trajectory of its growth and market acceptance.

Financial Data and Key Metrics Changes - Total revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of ZUSDURI and increased sales of JELMYTO [19][20] - The net loss for the year was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - ZUSDURI generated $15.8 million in revenue for 2025, reflecting early launch dynamics [5][14] - JELMYTO generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [7][17] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care with 102 unique prescribers and 32 repeat prescribers for ZUSDURI [15] - Over 95% of covered lives had open access to ZUSDURI by year-end 2025 [15] Company Strategy and Development Direction - The company’s top priority is the commercial launch of ZUSDURI, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5][7] - The company is advancing its pipeline with UGN-103 and UGN-104, with plans to submit an NDA for UGN-103 in the second half of 2026 [8][12] - A refinancing of the debt facility with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility [8][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early trajectory of ZUSDURI's launch and noted that the permanent J-code has facilitated more predictable patient access [5][6] - The company anticipates that the conversion timeline from patient enrollment forms to dosing will narrow as sites gain familiarity with the product [16] - Management is optimistic about the potential for ZUSDURI and its pipeline products to create long-term value for patients and shareholders [9][23] Other Important Information - The company expects JELMYTO net product revenues for 2026 to be in the range of $97 million to $101 million, reflecting a year-over-year growth rate of approximately 3% to 7% [23] - Full-year 2026 operating expenses are expected to be in the range of $240 million to $250 million, driven by increased sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for ZUSDURI - Management indicated that they would consider providing formal guidance for ZUSDURI after gaining visibility into steady-state demand, approximately two quarters post the permanent J-code [29] - The number of patient enrollment forms has increased since the permanent J-code became effective, with new and repeat prescribers contributing to this growth [31][32] Question: Trends in repeat prescribers and their likelihood of becoming repeat prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement and repeat prescribing [39] Question: Timing for UGN-103 market introduction and its commercial positioning - UGN-103 is expected to be introduced after obtaining a permanent J-code, with a potential launch in early 2028 [41] Question: Current use of ZUSDURI among patients and expected shifts in use patterns - ZUSDURI is being used primarily for patients who recur early, have frequent recurrences, or are unfit for surgery, with expectations for increased utilization as community practices gain experience [48][49] Question: Opportunities for ZUSDURI in the adjuvant setting - There is enthusiasm for expanding UGN-103 into the adjuvant setting for new diagnoses, with ongoing discussions about potential combinations with other agents [60][61]

Core Insights - UroGen Pharma Ltd. reported a transformative year in 2025, marked by the FDA approval and launch of ZUSDURI, the first approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with expectations of over $1 billion in peak sales opportunity [2][5][10] Financial Performance - Total revenue for 2025 was $109.8 million, a 21% increase from $90.4 million in 2024, primarily driven by ZUSDURI's launch and growth in JELMYTO sales [10] - JELMYTO generated net product sales of $94.0 million in 2025, reflecting a 7% year-over-year growth [4][5] - UroGen reported a net loss of $153.5 million for 2025, compared to a net loss of $126.9 million in 2024, with a loss per share of $3.19 [16][22] Product Developments - ZUSDURI achieved net sales of $15.8 million in its initial launch period in 2025, with a permanent J Code effective January 1, 2026, enhancing reimbursement processes [5][6] - The UTOPIA trial for UGN-103 showed a 77.8% complete response rate, with plans to submit a New Drug Application (NDA) in the second half of 2026 [12] - UroGen is advancing UGN-501, an investigational oncolytic virus therapy, with plans for an IND submission and Phase 1 trial initiation by the end of 2026 [8] Strategic Initiatives - The company refinanced its term loan with Pharmakon Advisors, securing $200 million to strengthen its balance sheet and support long-term growth strategies [9] - UroGen plans to explore label expansion opportunities for UGN-103 and continue evaluating lifecycle management strategies [12] Market Outlook - Guidance for 2026 JELMYTO sales is projected between $97 million and $101 million, indicating a growth rate of approximately 3% to 7% over 2025 [17] - The company is not providing full-year sales guidance for ZUSDURI at this time due to its early commercial stage [17]

ZUSDURI (formerly UGN-102) Approved by FDA! ZUSDURI is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer Transforming Urothelial Cancer Care Through Innovation March 2026 Disclaimers This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the estimated addressable patient population and market and revenue opportunity for ...

UroGen Pharma Conference Call Summary Company Overview - **Company**: UroGen Pharma (NasdaqGM:URGN) - **Founded**: In Israel, addressing unmet needs in treating urothelial cancers - **Technology**: RTGel platform, a reverse thermal gel that allows sustained release of medications in the bladder [5][6] Core Products - **Commercial Assets**: - **Jelmyto**: Approved for low-grade upper tract urothelial carcinoma (6,000 patients in the U.S.) - **ZUSDURI**: Recently approved for low-grade intermediate-risk bladder cancer (60,000 patients in the U.S.) [7][8] Market Opportunity - **Patient Demographics**: - 60,000 newly diagnosed recurrent patients annually, with 68% having two or more recurrences [16] - 20,000 recurrent newly diagnosed patients, with a significant prevalent pool of low-grade intermediate-risk patients [16] - **Unmet Medical Need**: Historically, treatment was limited to surgical intervention (TURBT), leading to high recurrence rates [13][14] Product Launch and Performance - **ZUSDURI Launch**: - Initial revenue of $1.8 million, with October revenue reaching $4.5 million, indicating strong early performance [19] - Permanent J-code introduced in January, expected to accelerate uptake [36] - **Market Penetration**: - Estimated peak sales potential for ZUSDURI is over $1 billion, requiring only 20% market share to achieve this [37] Clinical Data and Feedback - **Efficacy**: - ZUSDURI demonstrated an 80% complete response rate, with 80% of those patients maintaining response at 12 months [25] - 90% of patients preferred ZUSDURI over TURBT based on patient-reported outcomes [25] - **Physician Feedback**: Positive reception from physicians, with many expressing enthusiasm for a non-surgical treatment option [22][25] Competitive Landscape - **Positioning**: UroGen believes ZUSDURI is the best treatment option due to its non-surgical nature and compelling clinical data [45] - **Market Growth**: The entry of additional treatments is seen as beneficial for overall market growth, with UroGen confident in its unique offering [44] Future Developments - **Next Generation Products**: - UGN-103 and UGN-104 are in development for broader applications in bladder cancer [48][51] - UGN-501, an oncolytic virus, is being explored for potential use in other cancers beyond urothelial [52] - **Long-term Strategy**: UroGen aims to diversify its portfolio while maintaining a focus on urothelial and specialty cancers [52] Financial Guidance - **Revenue Guidance**: UroGen is not providing specific revenue guidance for the upcoming year but is confident in continued growth based on current trends [39][63] Summary of Key Metrics - **ZUSDURI Market Size**: 60,000 patients, with a potential peak sales of $1.2 billion at 20% market share [37] - **Jelmyto Growth**: Continued single-digit growth, with increased physician engagement [55] This summary encapsulates the key points discussed during the UroGen Pharma conference call, highlighting the company's innovative approach to treating urothelial cancers and its strategic market positioning.

UroGen Pharma FY Conference Summary Company Overview - UroGen Pharma focuses on delivering local medicine to the urothelium, addressing unmet needs in treating urothelial cancers with its innovative RT Gel technology, which transforms from liquid to gel at body temperature [6][7] Key Product: ZUSDURI - ZUSDURI is the first FDA-approved non-surgical option for intermediate-risk non-muscle-invasive bladder cancer (NMIBC) [8] - The product addresses a significant unmet need in treating low-grade, intermediate-risk NMIBC, which has a high recurrence rate [9][10] - Historical treatment involved TURBT procedures, which are invasive and not comprehensive [10][11] Commercial Launch Insights - The commercialization of ZUSDURI is complex, akin to a drug-device combination, requiring operational logistics and physician education [12][13] - The transition from patient enrollment to actual dosing can take up to 60 days, presenting a challenge in revenue recognition [15][17] - Initial sales figures indicated a slower start, but there is optimism about future growth as logistical hurdles are addressed [23][25] Reimbursement Dynamics - Revenue is recognized upon shipment, with a just-in-time inventory model [17][18] - The introduction of a permanent J-code in January is expected to enhance reimbursement confidence among physicians [19][21] - A service warranty is offered to assist physicians with reimbursement processes, although actual usage is anticipated to be low due to positive reimbursement experiences [20] Market Expectations - Approximately 70% of physicians are reportedly waiting for the J-code before using ZUSDURI [21] - Anticipated revenue growth post-J-code is expected to mirror previous experiences with similar products, with a projected 220% increase in revenue within six months [26][27] Competitive Landscape - The entry of competitors into the intermediate-risk space is viewed positively, as it can drive innovation and provide more options for patients [33][34] - UroGen's treatment offers a significant advantage with an 80% complete response rate without the need for surgery, compared to competitors that require surgical intervention [35] Future Developments - UGN-103 and UGN-104 are next-generation formulations with patent protection until 2041, aimed at replacing UGN-102 post-J-code [40][42] - The company is confident in its ability to transition from UGN-102 to UGN-103 without regulatory issues [48][50] Long-term Outlook - The company anticipates continued growth for Jelmyto, its first approved product, as awareness increases with the launch of UGN-102 [51] - 2026 is expected to be a pivotal year for UroGen, with the first two quarters crucial for demonstrating market potential [53]

Core Insights - UroGen Pharma Ltd. reported financial results for Q3 2025, highlighting the launch momentum of ZUSDURI, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer [1][2] - The company expressed optimism about the commercial potential of ZUSDURI, supported by strong physician engagement and broad reimbursement coverage [2][5] Financial Performance - Total revenues for Q3 2025 were $27.5 million, with JELMYTO generating $25.7 million, reflecting a year-over-year growth of approximately 13% [11][7] - ZUSDURI achieved net product revenue of $1.8 million in its first quarter, with preliminary estimates for October 2025 indicating $4.5 million, suggesting accelerating growth [11][6] - As of September 30, 2025, UroGen had $127.4 million in cash, cash equivalents, and marketable securities [17] Product Developments - ZUSDURI received a unique J-Code (J9282) effective January 1, 2026, enhancing patient access through various insurance programs [6] - The Phase 3 UTOPIA trial for UGN-103 reported a complete response rate of 77.8%, with plans to submit an NDA in the second half of 2026 [12][5] - UroGen discontinued the development of UGN-301 due to not meeting internal benchmarks, while continuing with UGN-103 and UGN-104 [12] Research and Development - R&D expenses for Q3 2025 were $14.0 million, driven by costs associated with the UTOPIA trial [13] - The company is focused on next-generation formulations to improve manufacturing efficiencies and extend product lifecycles [2][12] Operational Highlights - UroGen activated 592 sites of care and had 54 unique prescribers for ZUSDURI since its launch [6] - The company anticipates full-year 2025 net product revenues for JELMYTO to be between $94 million and $98 million, indicating an 8% to 12% growth from 2024 [18]

Core Insights - UroGen Pharma Ltd. announced preliminary results from the Phase 3 UTOPIA trial, showing a 77.8% three-month complete response (CR) rate for UGN-103 in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) [1][2] - The FDA has agreed that the results from the UTOPIA trial can support a New Drug Application (NDA) submission for UGN-103, marking a significant regulatory milestone for the company [2] Company Overview - UroGen Pharma is focused on developing innovative solutions for urothelial and specialty cancers, utilizing proprietary technologies like RTGel for sustained drug release [7] - The company has developed UGN-103, an improved formulation of mitomycin, which aims to enhance manufacturing and reconstitution processes while providing intellectual property protection until December 2041 [4][2] Clinical Trial Details - The UTOPIA trial is a single-arm, multicenter study involving 99 patients, with a primary endpoint of complete response rate at three months [3] - Patients received 75 mg of UGN-103 via intravesical instillation once weekly for six weeks, with responders entering a follow-up phase to assess durability of response [3] Competitive Landscape - UGN-103 is designed to offer key improvements over ZUSDURI, the first FDA-approved treatment for recurrent LG-IR-NMIBC, including a shorter manufacturing process and simplified reconstitution [2][4] - The U.S. market for LG-IR-NMIBC includes approximately 82,000 new cases annually, with around 59,000 being recurrent cases, indicating a significant patient population for UroGen's products [6]

Core Insights - UroGen Pharma Ltd. has completed patient enrollment in its Phase 3 UTOPIA clinical trial for UGN-103, a next-generation formulation for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) [1][3] Company Overview - UroGen Pharma is focused on developing innovative solutions for urothelial and specialty cancers, utilizing proprietary technologies like RTGel for sustained drug release [8] - The company aims to provide non-surgical treatment options for bladder cancer patients, with UGN-103 representing a significant advancement in its pipeline [3][5] Clinical Trial Details - The UTOPIA trial enrolled 99 patients globally and is a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 [2][3] - Patients receive 75 mg of UGN-103 via intravesical instillation once weekly for six weeks, with the primary endpoint being the complete response rate at three months [3] Product Information - UGN-103 is designed to improve upon ZUSDURI (mitomycin) by offering a shorter manufacturing process and simplified reconstitution [2][5] - UroGen has received a Notice of Allowance for patent protection of UGN-103, expected to last until December 2041 [4] Market Context - LG-IR-NMIBC affects approximately 82,000 people annually in the U.S., with around 59,000 cases being recurrent [7] - The median age of diagnosis for bladder cancer is 73 years, and up to 70% of NMIBC patients experience at least one recurrence [7]